WO2008057254A3 - Composés tricycliques servant d'inhibiteurs des métalloprotéases matricielles - Google Patents

Composés tricycliques servant d'inhibiteurs des métalloprotéases matricielles Download PDF

Info

Publication number
WO2008057254A3
WO2008057254A3 PCT/US2007/022651 US2007022651W WO2008057254A3 WO 2008057254 A3 WO2008057254 A3 WO 2008057254A3 US 2007022651 W US2007022651 W US 2007022651W WO 2008057254 A3 WO2008057254 A3 WO 2008057254A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
matrix metalloproteinase
metalloproteinase inhibitors
tricyclic compounds
compounds
Prior art date
Application number
PCT/US2007/022651
Other languages
English (en)
Other versions
WO2008057254A2 (fr
Inventor
Wei Li
Jianchang Li
Yuchuan Wu
Steve Tam
Tarek Mansour
Joseph P Sypek
Iain Mcfayden
Rajeev Hotchandani
Junjun Wu
Original Assignee
Wyeth Corp
Wei Li
Jianchang Li
Yuchuan Wu
Steve Tam
Tarek Mansour
Joseph P Sypek
Iain Mcfayden
Rajeev Hotchandani
Junjun Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Wei Li, Jianchang Li, Yuchuan Wu, Steve Tam, Tarek Mansour, Joseph P Sypek, Iain Mcfayden, Rajeev Hotchandani, Junjun Wu filed Critical Wyeth Corp
Priority to JP2009534660A priority Critical patent/JP2010507674A/ja
Priority to CA002667644A priority patent/CA2667644A1/fr
Priority to EP07839790A priority patent/EP2074107A2/fr
Priority to MX2009004289A priority patent/MX2009004289A/es
Publication of WO2008057254A2 publication Critical patent/WO2008057254A2/fr
Publication of WO2008057254A3 publication Critical patent/WO2008057254A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/76—Dibenzothiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) : et des sels, hydrates ou esters acceptables du point de vue pharmaceutique de ceux-ci, R1, R2, R3, R4, R5, X et Y étant tels que définis ici. La présente invention concerne également des procédés de fabrication des composés de formule (I) et des procédés de traitement d'affections ou troubles pathologiques induits entièrement ou en partie par des métalloprotéases matricielles, tels que l'asthme et une bronchopneumopathie chronique obstructive, lesquels consistent à administrer une quantité efficace du point de vue thérapeutique d'un composé de formule (I) à un mammifère (par exemple à un humain) qui en a besoin.
PCT/US2007/022651 2006-10-27 2007-10-26 Composés tricycliques servant d'inhibiteurs des métalloprotéases matricielles WO2008057254A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009534660A JP2010507674A (ja) 2006-10-27 2007-10-26 マトリクスメタロプロテアーゼ阻害剤としての三環式化合物
CA002667644A CA2667644A1 (fr) 2006-10-27 2007-10-26 Composes tricycliques servant d'inhibiteurs des metalloproteases matricielles
EP07839790A EP2074107A2 (fr) 2006-10-27 2007-10-26 Composes tricycliques servant d'inhibiteurs des metalloproteases matricielles
MX2009004289A MX2009004289A (es) 2006-10-27 2007-10-26 Compuestos triciclicos como inhibidores de metaloproteinasas matriciales.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85478606P 2006-10-27 2006-10-27
US60/854,786 2006-10-27

Publications (2)

Publication Number Publication Date
WO2008057254A2 WO2008057254A2 (fr) 2008-05-15
WO2008057254A3 true WO2008057254A3 (fr) 2009-01-08

Family

ID=39166382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022651 WO2008057254A2 (fr) 2006-10-27 2007-10-26 Composés tricycliques servant d'inhibiteurs des métalloprotéases matricielles

Country Status (5)

Country Link
EP (1) EP2074107A2 (fr)
JP (1) JP2010507674A (fr)
CA (1) CA2667644A1 (fr)
MX (1) MX2009004289A (fr)
WO (1) WO2008057254A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR066412A1 (es) * 2007-05-04 2009-08-19 Wyeth Corp Derivados de dibenzofurano y dibenzotiofeno, composiciones farmaceuticas que los contienen y usos en patologias tales como trastornos oseos, crecimiento de tumores, diabetes y obesidad.
CA2747670A1 (fr) 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Composes carbazole carboxamide utiles comme inhibiteurs de kinases
US9273021B2 (en) 2009-02-05 2016-03-01 Trustees Of Boston College Dibenzofuran derivatives as inhibitors of fructose 1,6-bisphosphatase and methods of use thereof
FR2949463B1 (fr) 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
FR2996003B1 (fr) 2012-09-25 2014-10-17 Commissariat Energie Atomique Methode pour detecter specifiquement dans un echantillon une metalloprotease matricielle (mmp) d'interet uniquement dans sa forme active
BR112015021452A2 (pt) 2013-03-15 2017-07-18 Monsanto Technology Llc azóis n-,c-dissubstituídos para controlar pragas de nematódeos
US9981928B2 (en) 2013-06-20 2018-05-29 Bayer Cropscience Aktiengesellschaft Aryl sulfide derivatives and aryl sulfoxide derivatives as acaricides and insecticides
EP2907512A1 (fr) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibiteurs de MMP-12 en tant qu'agents antiviraux
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3394033T3 (da) 2015-12-22 2021-01-04 Incyte Corp Heterocykliske forbindelser som immunmodulatorer
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3504198B1 (fr) 2016-08-29 2023-01-25 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
US10042251B2 (en) 2016-09-30 2018-08-07 Rohm And Haas Electronic Materials Llc Zwitterionic photo-destroyable quenchers
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
EP3558985B1 (fr) 2016-12-22 2022-09-07 Incyte Corporation Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3558989B1 (fr) 2016-12-22 2021-04-14 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3790877B1 (fr) 2018-05-11 2023-03-01 Incyte Corporation Dérivés de tétrahydro-imidazo[4,5-c]pyridine en tant qu'immunomodulateurs de pd-l1
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
TW202126652A (zh) 2019-09-30 2021-07-16 美商英塞特公司 作為免疫調節劑之吡啶并［３，２—ｄ］嘧啶化合物
AU2020385113A1 (en) 2019-11-11 2022-05-19 Incyte Corporation Salts and crystalline forms of a PD-1/PD-L1 inhibitor
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
CA3200844A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Processus de fabrication d'un inhibiteur pd-1/pd-l1 ainsi que de ses sels et formes cristallines

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09194481A (ja) * 1996-01-11 1997-07-29 Eisai Co Ltd 縮合四環式ヘテロ環誘導体
WO1998009957A1 (fr) * 1996-09-04 1998-03-12 Warner-Lambert Company Composes et procede destines a l'inhibition de metalloproteases matricielles
WO1998009934A1 (fr) * 1996-09-04 1998-03-12 Warner-Lambert Company Inhibiteurs de metalloproteinases matricielles et leurs utilisations pharmaceutiques
JPH11246527A (ja) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
EP1233017A1 (fr) * 2001-02-14 2002-08-21 Warner-Lambert Company Sulphonamides tricycliques utiles comme inhibiteurs de métalloprotéase matricielle
US20050027129A1 (en) * 2003-04-11 2005-02-03 Glenmark Pharmaceuticals, Inc. Usa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09194481A (ja) * 1996-01-11 1997-07-29 Eisai Co Ltd 縮合四環式ヘテロ環誘導体
WO1998009957A1 (fr) * 1996-09-04 1998-03-12 Warner-Lambert Company Composes et procede destines a l'inhibition de metalloproteases matricielles
WO1998009934A1 (fr) * 1996-09-04 1998-03-12 Warner-Lambert Company Inhibiteurs de metalloproteinases matricielles et leurs utilisations pharmaceutiques
JPH11246527A (ja) * 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
EP1233017A1 (fr) * 2001-02-14 2002-08-21 Warner-Lambert Company Sulphonamides tricycliques utiles comme inhibiteurs de métalloprotéase matricielle
US20050027129A1 (en) * 2003-04-11 2005-02-03 Glenmark Pharmaceuticals, Inc. Usa Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 1997, Derwent World Patents Index; AN 1997-431459, XP002500619 *
DATABASE WPI Week 1999, Derwent World Patents Index; AN 1999-566553, XP002473193 *
EL-NAGGAR A M ET AL: "Synthesis and biological activity of some new dibenzofuran- and 7-nitrodibenzofuran-2-sulfonyl amino acid derivatives", ACTA PHARMACEUTICA JUGOSLAVICA, SAVEZ FARMACEUTSKIH DRUSTAVA JUGOSLAVIJE, ZAGREB, YU, vol. 35, no. 1, 1 January 1985 (1985-01-01), pages 15 - 22, XP009097421, ISSN: 0001-6667 *

Also Published As

Publication number Publication date
JP2010507674A (ja) 2010-03-11
EP2074107A2 (fr) 2009-07-01
WO2008057254A2 (fr) 2008-05-15
MX2009004289A (es) 2009-05-05
CA2667644A1 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008057254A3 (fr) Composés tricycliques servant d'inhibiteurs des métalloprotéases matricielles
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
WO2006124692A3 (fr) Inhibiteurs 3-cyanoquinoline de la tpl2 kinase et procedes de production et d'utilisation associes
WO2007056167A3 (fr) (quinazolinyl)phenyl-thiophenyl-sulfonylurees substituees et procedes pour les preparer
WO2006002434A3 (fr) Nouveaux indazole carboxamides et leur utilisation
WO2010018113A3 (fr) Bi-aryle aminotétralines
WO2008137816A3 (fr) Composés tricycliques en tant qu'inhibiteurs de métalloprotéinase matricielle
WO2009126530A3 (fr) Antagonistes du récepteur cgrp
WO2010018109A3 (fr) Aminotétralines substituées
WO2011005811A8 (fr) Polythérapie pour le traitement du diabète
WO2012083112A3 (fr) Inhibiteurs de cyp11b, cyp17 et/ou cyp21
WO2008127682A3 (fr) Combinaison d'une thérapie anticoagulante à un composé agissant en tant qu'inhibiteur de facteur xa
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
EA200970883A1 (ru) Индолкарбоксамиды как ингибиторы ikk2
EA200970158A1 (ru) Производные хинуклидина в качестве антагонистов м3
NZ591914A (en) Naphthylacetic acids
WO2010018112A3 (fr) Monoaryle aminotétralines
NZ599099A (en) Phenyloxadiazole derivatives as pgds inhibitors
WO2006011024A3 (fr) Nouveaux composes tricycliques utilises dans le traitement de troubles inflammatoires et allergiques, procede de preparation associe, et compositions pharmaceutiques les contenant
EA200800183A1 (ru) Новые производные индолкарбоксамида, содержащая их фармацевтическая композиция и способ лечения
WO2008137809A3 (fr) Sels de [4(-(6-fluoro-7-méthylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phényl]-5-chloro-thiophén-2-yl-sulfonylurée, formes et procédés qui leur sont associés
WO2004075840A3 (fr) Modulateurs selectifs de recepteurs de glucocorticoides non steroidaux
TW200640905A (en) Monopotassium salt of an IκB kinase inhibitor
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839790

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007839790

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004289

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009534660

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2667644

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE